WP
PRVB

WealthShield Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

WealthShield Partners’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$10K – 1209
2021
Q1 		$10K Buy
+1,000
New +$14.1K ﹤0.01% 815

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

WealthShield Partners's PRVB Position: Q2 2021 in Review

WealthShield Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2021, closing a stake of 1,000 shares — an estimated $10K sold.

WealthShield Partners first reported a position in PRVB in Q1 2021 and held it in 1 quarter. The position peaked at $10K in Q1 2021. 125 funds tracked by Wall St. Rank hold PRVB as of Q2 2021.

  • WealthShield Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • WealthShield Partners sold 1,000 Provention Bio, Inc. Common Stock shares in Q2 2021, an estimated $10K.
  • WealthShield Partners first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • WealthShield Partners's Provention Bio, Inc. Common Stock position peaked at $10K in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2021.

Based on WealthShield Partners's 13F filing for Q2 2021, filed 6 Aug 2021.